Randomized trial demonstrates improved wound closure in diabetic wounds, suggesting a new therapeutic strategy.
Diabetic wounds often arise from a dysregulated wound microenvironment characterized by persistent inflammation, impaired angiogenesis, and aberrant macrophage polarization, leading to delayed healing and severe disability. In this study, we fabricated a stem cell-derived artificial nanovesicles-salidroside@gelatin methacryloyl/polyvinyl alcohol composite microneedle system (CNV-Sa@GelMA/PVA-MN) composed of a GelMA/PVA hydrogel matrix integrated with salidroside loaded stem cell-derived artificial nanovesicles to achieve efficient therapy for diabetic wound. The system penetrated the skin barrier for precise delivery, with stem cell-derived artificial nanovesicles enabling sustained salidroside release and collectively enhancing its anti-inflammatory and pro-angiogenic activities in vitro. Mechanistically, network pharmacology, molecular dynamics simulations, and proteomics revealed the system suppressed the NF-κB pathway, promoted macrophage M1 to M2 polarization, and alleviated inflammatory responses. In vivo experiments confirmed it significantly accelerated wound closure and inhibited inflammatory factor release. These findings highlighted a promising strategy for diabetic wound therapy through inflammatory microenvironment regulation and coordinated tissue repair.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: